Katzenell Dimant /

KD Represents Kitov in Acquisition of TyrNovo



We are proud of our client Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical drug development company, for expanding their pipeline through the acquisition of a majority stake in TyrNovo Ltd., a privately held developer of novel small molecules in the immuno-oncology therapeutic field.

Read the press on TheMarker, PRNewswire, Genetic Engineering & Biotechnology News


See some other notable transactions lead by our Hi-Tech & Life Sciences practice


read more in: